"WEIGH TO GO" WEIGHT LOSS CENTERS

SEMAGLUTIDE PLUS CARNITINE FOR WEIGHTLOSS

A New Potent Once Weekly Weight Loss Injection

Semaglutide 2.65mg / L-Carnitine 100mg / ml

Dosing Regimen:

For the 1st 4 weeks the dose should be only 0.1ml or 10 units. The dose only if needed for more appetite suppression can be titrated to 0.2ml or 20 units for weeks 5-8. Stay with the same dose if losing weight with no side effects. If there is no weight loss or no appetite suppression or cessation and no side effects then increase to 30 units weeks 9-12 and then 40 units weeks 13-16. No more than 50 units per week is recommended after week 16.

We strongly recommend a weekly subcutaneous injection that can be taken with Megaburn and or B12 for the best results with a healthy lifestyle modification. It is a very potent medication, so titrating the dose slowly is extremely important to decrease the side effect profile of Gastrointestinal issues.

Semaglutide is ideal for patients who have a considerable amount of weight to lose. A powerful appetite suppressant, semaglutide with carnitine can help patients lose more weight with a healthy lifestyle implementation.

Semaglutide works by binding to and activating the GLP-1 receptor, it stimulates insulin secretion and lowers glucagon secretion when blood glucose levels are high. It also causes a slowing down in how fast the stomach empties and signals to the brain a feeling of fulness. This results in a very powerful and lasting appetite suppression for most patients in addition to improving blood sugar levels.

Carnitine is a potent fat mobilization amino acid.

Most common side effects can include:

Nausea, increase in heart rate, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, retinal disorder (diabetes mellitus patients), hypoglycemia (diabetes mellitus patients), flatulence, gastroenteritis, GERD, gastritis, alopecia, lipase increase, amylase increase, injection site reaction, hypotension

Serious Reactions: hypersensitivity reaction, anaphylaxis, angioedema, acute kidney injury, chronic renal failure exacerbation, pancreatitis, cholelithiasis, cholecystitis, syncope

Black Box Warning: Animal studies showed thyroid C-Cell Tumor, contraindicated with in patients with MTC history or in MEN2, uncertain value of routine serum calcitonin or thyroid ultrasound monitoring